CJC-1295 (DAC) Mechanism of Action

CJC-1295 Overview & Molecular Profile

MECHANISM OF ACTION

CJC-1295 is a synthetic GHRH analog built on the first 29 amino acids of GHRH with a Drug Affinity Complex (DAC) lysine modification that enables covalent binding to serum albumin. This albumin binding extends the half-life from minutes to 6–8 days, enabling once-weekly dosing with sustained GH and IGF-1 elevation. First described in a 2006 JCEM study, it exists in two forms: with DAC (long-acting) and without DAC (Modified GRF 1-29; ~30-minute half-life).

Mechanism of Action: Hormonal Signaling & Receptor Binding

MOLECULAR STRUCTURE

CJC-1295 acts on the GHRH receptor in the pituitary gland to stimulate growth hormone release. The DAC modification allows the peptide to bind covalently to serum albumin after injection, protecting it from enzymatic degradation and extending its biological half-life from minutes to days. This results in sustained elevation of GH and IGF-1 levels. The peptide amplifies the natural GH pulsatile release pattern rather than creating artificial spikes.

Drug Affinity Complex: Engineering a 6-8 Day GHRH Analog

CJC-1295 represents a unique approach to peptide half-life extension: covalent albumin conjugation via a Drug Affinity Complex (DAC). Unlike the reversible albumin binding used by GLP-1 agonists, the DAC forms an irreversible bond with serum albumin, creating a circulating depot that extends the half-life of a GHRH analog from minutes to days.

The DAC Covalent Albumin-Binding Mechanism

The Drug Affinity Complex technology was specifically developed to overcome the rapid degradation of GHRH analogs, which have half-lives measured in minutes without modification. • A maleimidopropionyl-lysine linker reacts with Cys34 on serum albumin after subcutaneous injection, forming an irreversible thioether covalent bond. This conjugation extends the half-life from approximately 30 minutes (for unmodified Mod GRF 1-29) to 6-8 days. • A single subcutaneous dose produces dose-dependent GH elevation sustained over the full 6-8 day half-life period, with IGF-1 elevation persisting up to 14 days (approximately 2x baseline). • Without DAC (marketed as Mod GRF 1-29 or Modified GRF), the peptide retains the same GHRH receptor agonist activity but requires 2-3 daily administrations due to the ~30-minute half-life.

Pulsatile GH Amplification, Not Constant Elevation

A critical distinction in CJC-1295's pharmacodynamics is that it amplifies the body's natural pulsatile GH secretion rather than creating a constant, non-physiologic GH level. • CJC-1295 enhances the amplitude of endogenous GH pulses — each natural GH secretory episode is amplified by the persistent GHRH receptor stimulation, rather than being replaced by a flat, elevated GH concentration. • This preservation of pulsatility distinguishes CJC-1295 from exogenous GH administration, which suppresses endogenous GH pulsatility through negative feedback. • The combination of CJC-1295 (GHRH analog) with a GHRP such as Ipamorelin (GHSR-1a agonist) produces synergistic GH release — the two receptor pathways converge on the somatotroph to produce GH secretion greater than either agent alone.

Sustained GH Elevation

Research demonstrates that CJC-1295 with DAC produces remarkably prolonged elevation of growth hormone levels lasting 6-8 days following a single subcutaneous injection, fundamentally different from the short-lived pulses produced by other GH-releasing compounds. The Drug Affinity Complex binds covalently to albumin in the bloodstream, protecting the peptide from enzymatic degradation and extending its biological activity dramatically. Studies show 2-10 fold elevations in mean GH levels that persist throughout the week, while importantly maintaining the natural pulsatile secretion pattern rather than creating unnatural constant elevation. This sustained release profile has made CJC-1295 valuable for research into growth hormone replacement strategies, aging-related GH decline, and optimization of GH therapy protocols. The extended half-life also enables study of long-term GH elevation effects without the confounding variable of repeated daily injections.